MSTN and Cirrhosis: Previous studies showed that serum myostatin also had good prognostic performance of survival and HCC development in a population of whom 58.6% had predominantly hepatitis C virus (HCV)-related liver cirrhosis [9] and 39.4% had hepatitis B virus (HBV)-related cirrhosis [14].